To choose between parametric or non-parametric test is a very difficult and complex decision. In contrast to Dr Najmi’s views behavioral scientists rarely have data meeting the assumption of the parametric tests. The data from behavioral research do not allow the use of parametric tests, since they do not meet the criteria for such tests. Therefore, non-parametric

tests Inhibitors,research,lifescience,medical play a prominent role in the analysis and of data obtained from investigations in behavioral and social sciences.7 Moreover, the researchers’ knowledge about the population from which the data are obtained defines which group of tests is appropriate to be used in a study.7 On the other hand in studies involving large samples it is possible to use non-parametric tests instead of parametric tests. Indeed using parametric or non-parametric Inhibitors,research,lifescience,medical tests don’t cause Quisinostat problem in these situations.8 In conclusion, it is almost impossible to find a study in which cofounders are totally controlled. Obviously, the before-after Inhibitors,research,lifescience,medical design may suffer from the impact

that pretest could have on post-test, or from simultaneous events. However, in our study only two months were allowed between pre counseling and post counseling measurements. It doesn’t seem that family members who knew of the HIV status of their patients and revealed a particular behavior toward Inhibitors,research,lifescience,medical them for several years could change their behavior significantly as a result of events other than counseling practiced in the study.
Background: Statins, such as simvastatin, are the drugs of choice for the treatment of hypercholesterolemia. On the other hand hypercholesterolmia can

occur in hypothyroid patients, who receive levothyroxine. There are few clinical case reports in regards to drug interaction between levothyroxine Inhibitors,research,lifescience,medical and lovastatin or simvastatin, indicating decreased levothyroxine effects. This study aimed at determining possible interaction between simvastatin and levothyroxine in hypothyroid patients by assessing many serum levels of thyroid stimulating hormone (TSH) and free thyroxine (FT4), the two important laboratory indices for levothyroxine therapy. Methods: In a cross sectional study, 41 eligible hypothyroid patients receiving levothyroxine (50-150 µg/d) were selected. Blood samples were taken before and after three months of simultaneous treatment with simvastatin (20 mg/d) and levothyroxine to determine the serum levels of TSH and FT4. Results: There was no significant difference between the serum levels of TSH (P=0.77) or FT4 (P=0.76) before and after three months of simultaneous treatment. Also, there was no aggravation or initiation of any sign or symptom of hypothyroidism in the patients during the study period.